Read More: https://www.cnbc.com/2025/02/04/merck-mrk-earnings-q4-2024.html

Merck's recent decision to halt Gardasil vaccine shipments to China has significantly impacted its stock market performance, leading to a revised revenue outlook for 2025 that falls short of analysts' expectations. This development raises concerns about the company's growth trajectory as it navigates the complexities of international vaccine distribution. Investors are now left wondering how this pause will affect Merck's standing in the competitive pharmaceutical landscape and whether it can recover from this setback. With the revenue forecast adjusted to a range between $64.1 billion and $65.6 billion, the market is keenly watching for any further implications of this announcement.